Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Operating Margin (2016 - 2025)

Cytokinetics (CYTK) has disclosed Operating Margin for 16 consecutive years, with 248.64% as the latest value for Q4 2025.

  • On a quarterly basis, Operating Margin changed N/A to 248.64% in Q4 2025 year-over-year; TTM through Dec 2025 was 409.28%, a N/A change, with the full-year FY2025 number at 695.44%, down 211781.0% from a year prior.
  • Operating Margin was 248.64% for Q4 2025 at Cytokinetics, up from 9856.3% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 1022.4% in Q2 2024 to a low of 32345.24% in Q3 2023.
  • A 5-year average of 7813.18% and a median of 4311.77% in 2022 define the central range for Operating Margin.
  • Peak YoY movement for Operating Margin: plummeted -2803347bps in 2023, then surged 1509956bps in 2024.
  • Cytokinetics' Operating Margin stood at 54.16% in 2021, then tumbled by -11884bps to 6491.06% in 2022, then dropped by -17bps to 7620.69% in 2023, then tumbled by -299bps to 30410.58% in 2024, then surged by 99bps to 248.64% in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Operating Margin are 248.64% (Q4 2025), 9856.3% (Q1 2025), and 30410.58% (Q3 2024).